Najat Khan, Ph.D., is an accomplished biopharma leader at the forefront of driving bold innovation to bring transformative therapies to patients. Building on a track record of integrating science, AI/data science, and business leadership across both large pharma and emerging TechBio, she serves as Chief R&D Officer, Chief Commercial Officer, and Board Member at Recursion, where she is advancing an AI-native approach to discovering, developing, and delivering novel medicines to address unmet patient needs.
At Recursion, Dr. Khan has combined bold vision with disciplined leadership to advance value and impact. She has sharpened the company’s portfolio and optimized resource allocation across its pipeline and operations – prioritizing and progressing multiple first-in-class and best-in-class clinical programs in oncology, rare disease, neuroscience, and inflammation & immunology, both internally and with partners such as Sanofi and Roche/Genentech.
Dr. Khan also helped lead Recursion’s combination with Exscientia – the largest TechBio deal of 2024 – and has expanded the Recursion OS 2.0 platform into an end-to-end engine for drug discovery and development, spanning biology, chemistry, and ClinTech. She has helped build a world-class “bilingual” team fluent in both science and data science and engages deeply with analysts, investors, and other stakeholders to strengthen understanding of Recursion’s model and shape broader conversations about the future of biopharma and TechBio.
Previously, Dr. Khan was Chief Data Science Officer and Senior Vice President, Global Head of Strategy, Portfolio & Operations for R&D at Johnson & Johnson Innovative Medicine. There, she helped triple pipeline value and advance 10 potential blockbusters, while leading J&J’s efforts to become one of the first major pharma companies to strategically embed AI and digital health across the R&D value chain. She also co-chaired the enterprise-wide Data Science Council, helping to accelerate adoption of data science across the company.
Dr. Khan has also been instrumental in founding industry consortia, including DISRUPT and the AI in Structural Biology Consortium; serves on the board of the Alliance for Artificial Intelligence in Healthcare; and is a member of Chief, a network for women in senior leadership. She holds a Ph.D. in Organic Chemistry from the University of Pennsylvania.
What is Najat Khan's net worth?
The estimated net worth of Najat Khan is at least $3.29 million as of August 18th, 2025. Khan owns 668,197 shares of Recursion Pharmaceuticals stock worth more than $3,287,529 as of December 4th. This net worth approximation does not reflect any other assets that Khan may own. Learn More about Najat Khan's net worth.
How do I contact Najat Khan?
Has Najat Khan been buying or selling shares of Recursion Pharmaceuticals?
Najat Khan has not been actively trading shares of Recursion Pharmaceuticals over the course of the past ninety days. Most recently, Najat Khan sold 36,599 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.52, for a transaction totalling $202,026.48. Following the completion of the sale, the insider now directly owns 668,197 shares of the company's stock, valued at $3,688,447.44. Learn More on Najat Khan's trading history.
Who are Recursion Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Recursion Pharmaceuticals?
In the last year, insiders at the sold shares 2 times. They sold a total of 256,599 shares worth more than $1,163,426.48. The most recent insider tranaction occured on December, 2nd when Director Blake Borgeson sold 220,000 shares worth more than $961,400.00. Insiders at Recursion Pharmaceuticals own 8.4% of the company.
Learn More about insider trades at Recursion Pharmaceuticals. Information on this page was last updated on 12/2/2025.
